STOCK TITAN

Xencor Doses First Subject in Phase 1/2 Study of XmAb®942 in Development for Patients with Inflammatory Bowel Disease

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)

Xencor (NASDAQ: XNCR) has initiated dosing of healthy volunteers in the first-in-human study of XmAb®942, a high-potency extended half-life anti-TL1A antibody for inflammatory bowel disease. The Phase 1/2 randomized, double-blind, placebo-controlled study will be conducted in three parts: Phase 1 Part A for single-ascending dose cohorts, Part B for repeat doses in healthy volunteers, and Phase 2 Part C for ulcerative colitis patients. Initial data is expected in the first half of 2025. The company believes XmAb942's properties may offer improved clinical benefits and more convenient dosing compared to other anti-TL1A antibodies in development.

Xencor (NASDAQ: XNCR) ha avviato la somministrazione a volontari sani nello studio di prima applicazione umana di XmAb®942, un anticorpo anti-TL1A ad alta potenza e a lunga durata per le malattie infiammatorie intestinali. Lo studio randomizzato, in doppio cieco e controllato con placebo di Fase 1/2 sarà condotto in tre parti: Fase 1 Parte A per coorti di dosi singole in aumento, Parte B per dosi ripetute in volontari sani e Parte 2 Parte C per pazienti con colite ulcerosa. I dati iniziali sono attesi nella prima metà del 2025. L'azienda crede che le proprietà di XmAb942 possano offrire benefici clinici migliorati e una somministrazione più conveniente rispetto ad altri anticorpi anti-TL1A in sviluppo.

Xencor (NASDAQ: XNCR) ha iniciado la dosificación en voluntarios sanos en el primer estudio en humanos de XmAb®942, un anticuerpo anti-TL1A de alta potencia y vida media prolongada para enfermedades inflamatorias del intestino. El estudio aleatorizado, doble ciego y controlado con placebo de Fase 1/2 se llevará a cabo en tres partes: Fase 1 Parte A para cohorte de dosis únicas en aumento, Parte B para dosis repetidas en voluntarios sanos, y Parte 2 Parte C para pacientes con colitis ulcerosa. Se espera que los datos iniciales estén disponibles en la primera mitad de 2025. La compañía cree que las propiedades de XmAb942 pueden ofrecer beneficios clínicos mejorados y una dosificación más conveniente en comparación con otros anticuerpos anti-TL1A en desarrollo.

Xencor (NASDAQ: XNCR)는 염증성 장 질환을 위한 고효능의 장시간 작용하는 항-TL1A 항체인 XmAb®942의 인체 최초 연구에서 건강한 자원자에 대한 투여를 시작했습니다. 이 1/2 단계 무작위 이중 맹검 위약 대조 연구는 세 부분으로 나누어 수행됩니다: 1단계 A 부문은 단일 상승 용량 집단을 위한 것이고, B 부문은 건강한 자원자에 대한 반복 용량을 위한 것이며, 2단계 C 부문은 궤양성 대장염 환자를 위한 것입니다. 초기 데이터는 2025년 상반기에 예상됩니다. 회사는 XmAb942의 특성이 개발 중인 다른 항-TL1A 항체에 비해 개선된 임상 혜택과 보다 편리한 투여를 제공할 수 있다고 믿고 있습니다.

Xencor (NASDAQ: XNCR) a lancé l'administration de doses à des bénévoles en bonne santé dans la première étude chez l'homme de XmAb®942, un anticorps anti-TL1A à haute puissance et à longue durée d'action pour les maladies inflammatoires de l'intestin. L'étude aléatoire, à double insu et contrôlée par placebo de Phase 1/2 sera réalisée en trois parties : Phase 1 Partie A pour des cohortes de doses uniques en augmentation, Partie B pour des doses répétées chez des bénévoles en bonne santé, et Phase 2 Partie C pour des patients atteints de colite ulcéreuse. Les premières données sont attendues dans la première moitié de 2025. La société estime que les propriétés de XmAb942 pourraient offrir des avantages cliniques améliorés et un mode d'administration plus pratique par rapport aux autres anticorps anti-TL1A en développement.

Xencor (NASDAQ: XNCR) hat mit der Dosisvergabe an gesunde Probanden in der ersten menschlichen Studie zu XmAb®942, einem hochpotenten, langwirksamen Anti-TL1A-Antikörper für entzündliche Darmerkrankungen, begonnen. Die Phase 1/2 randomisierte, doppelblinde, placebokontrollierte Studie wird in drei Teilen durchgeführt: Phase 1 Teil A für einstufig ansteigende Dosierungsgruppen, Teil B für wiederholte Dosen bei gesunden Probanden und Phase 2 Teil C für Patienten mit ulzerativer Kolitis. Erste Daten werden in der ersten Hälfte von 2025 erwartet. Das Unternehmen glaubt, dass die Eigenschaften von XmAb942 verbesserte klinische Vorteile und eine bequemere Dosierung im Vergleich zu anderen entwickelten Anti-TL1A-Antikörpern bieten könnten.

Positive
  • Initiation of Phase 1/2 clinical trial for XmAb942
  • Potential for improved clinical benefits and convenient dosing regimen
  • Clear development timeline with initial data expected in H1 2025
Negative
  • None.

Insights

The initiation of Phase 1/2 clinical trials for XmAb942 represents a significant milestone in Xencor's inflammatory bowel disease (IBD) program. The study's design, incorporating both healthy volunteers and ulcerative colitis patients, follows a robust three-part approach. The antibody's engineered properties for enhanced potency and extended half-life could potentially address key limitations of current IBD treatments. While the initial data expected in H1 2025 makes this a longer-term catalyst, successful development could position Xencor competitively in the growing IBD market, estimated to reach $20 billion by 2025. The emphasis on improved clinical benefits and convenient dosing could differentiate XmAb942 from other anti-TL1A antibodies in development, though market impact remains contingent on clinical results.

PASADENA, Calif.--(BUSINESS WIRE)-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that it has initiated dosing of healthy volunteers in the first-in-human study of XmAb®942, an investigational high-potency extended half-life anti-TL1A antibody. Xencor continues to expect initial data from the ongoing study during the first half of 2025.

“An anti-TL1A antibody engineered for improved target coverage with long duration of action could transform the clinician’s therapeutic toolbox in inflammatory bowel disease,” said Kenneth Hung, M.D., Ph.D., senior vice president, clinical development at Xencor. “We are excited to announce this first dosing of XmAb942 in healthy participants and believe that XmAb942’s properties, including potentially class-leading potency, may result in a therapeutic option with improved clinical benefit and a more convenient dosing regimen than other anti-TL1A antibodies currently in clinical development.”

The Phase 1/2 randomized, double-blind, placebo-controlled study of XmAb942 will be conducted in three parts. In Phase 1, Part A will enroll healthy volunteers into single-ascending dose (SAD) cohorts, and additional healthy volunteers would receive repeat doses in Part B. In Phase 2, Part C will enroll patients with ulcerative colitis who would receive the dosing determined from Parts A and B. (ClinicalTrials.gov Identifier: NCT06619990)

Xencor’s poster with preclinical characterization of XmAb942 was presented at the United Europe Gastroenterology Week (UEGW) in October 2024. The poster is archived under the “Publications” and the "Events & Presentations" pages of the Company's website located at www.xencor.com.

About XmAb®942

XmAb®942 is a high-potency, extended half-life, investigational anti-TL1A antibody in development for patients with inflammatory bowel disease, such as ulcerative colitis (UC) and Crohn’s disease (CD). The first generation of anti-TL1A antibodies, designed to block the interaction between the death receptor 3 (DR3) receptor and its ligand tumor necrosis factor (TNF)-like cytokine 1A (TL1A), have reduced disease activity in patients with UC and CD in multiple clinical studies. XmAb942’s half-life is enabled by Xencor’s validated Xtend™ Fc domain and could potentially support an eight- to twelve-week dosing interval in humans. Xencor initiated a Phase 1 dose-escalation study of XmAb942 in healthy volunteers in the fourth quarter of 2024.

About Xencor

Xencor is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of patients with cancer and other serious diseases. More than 20 candidates engineered with Xencor's XmAb® technology are in clinical development, and multiple XmAb medicines are marketed by partners. Xencor's XmAb engineering technology enables small changes to a protein’s structure that result in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.

Forward-Looking Statements

Certain statements contained in this press release may constitute forward-looking statements within the meaning of applicable securities laws. Forward-looking statements include statements that are not purely statements of historical fact, and can generally be identified by the use of words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “seek,” “look forward,” “believe,” “committed,” “investigational,” and similar terms, or by express or implied discussions relating to Xencor’s business, including, but not limited to, statements regarding expectations for clinical progress, planned receipt and presentations of clinical data, including the timing thereof, planned clinical trials, the quotations from Xencor's senior vice president, clinical development, and other statements that are not purely statements of historical fact. Such statements are made on the basis of the current beliefs, expectations, and assumptions of the management of Xencor and are subject to significant known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements and the timing of events to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. Such risks include, without limitation, the risks associated with the process of discovering, developing, manufacturing and commercializing drugs that are safe and effective for use as human therapeutics and other risks, including the ability of publicly disclosed preliminary clinical trial data to support continued clinical development and regulatory approval for specific treatments, and risks related to delays in receiving data from clinical trials, in each case as described in Xencor's public securities filings. For a discussion of these and other factors, please refer to Xencor's annual report on Form 10-K for the year ended December 31, 2023 as well as Xencor's subsequent filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended to date. All forward-looking statements are qualified in their entirety by this cautionary statement and Xencor undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.

Charles Liles

cliles@xencor.com

(626) 737-8118

For Media:

Cassidy McClain

Inizio Evoke

cassidy.mcclain@inizioevoke.com

(619) 694-6291

Source: Xencor, Inc.

FAQ

When will Xencor (XNCR) release initial data for XmAb942 trial?

Xencor expects to release initial data from the XmAb942 trial during the first half of 2025.

What is the design of Xencor's (XNCR) XmAb942 Phase 1/2 clinical trial?

The trial is a randomized, double-blind, placebo-controlled study conducted in three parts: Phase 1 Part A for single-ascending doses in healthy volunteers, Part B for repeat doses in healthy volunteers, and Phase 2 Part C for ulcerative colitis patients.

What condition is Xencor's (XNCR) XmAb942 being developed to treat?

XmAb942 is being developed for the treatment of inflammatory bowel disease, specifically including ulcerative colitis patients in Phase 2 of the trial.

Xencor, Inc.

NASDAQ:XNCR

XNCR Rankings

XNCR Latest News

XNCR Stock Data

1.51B
69.93M
0.86%
91.9%
6.84%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
PASADENA